The efficacy of a new formulation of trimethoprim and sulphadiazine in acute exacerbations of chronic bronchitis.
Thirty-four acute exacerbations of chronic bronchitis were treated using a new formulation of trimethoprim and sulphadiazine. Significant bacterial isolates were obtained in 18 exacerbations of which 12 comprised Haemophilus influenzae. Adverse effects of treatment, principally nausea, occurred in 5 patients. A satisfactory clinical response in association with the achievement of mucoid sputum was obtained in 94% and the mean time for sputum conversion of 3.8 days compares favourably with other antibiotics.
D000328:Adult; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D002908:Chronic Disease; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D013183:Sputum / Q000382:microbiology; D013411:Sulfadiazine / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D004338:Drug Combinations; D013411:Sulfadiazine; D014295:Trimethoprim; C024873:sulfadiazine, trimethoprim drug combination; D000096926:Benzenesulfonamides